Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 2/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 5/20 | 0.51 |
| ▸ | EGFR | P00533 | 12/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20051017 | 0.89 | PDE10A (0.43) | ENPP1PDE10ALCKEGFRKDR | |
| SCHEMBL20813470 | 0.87 | EGFR (0.52) | LCKEGFRKDRGAKRET | |
| SCHEMBL20813476 | 0.87 | EGFR (0.52) | LCKEGFRKDRGAKRET | |
| SCHEMBL3301604 | 0.81 | KDM1A (0.58) | EGFRKDRGAKFLT1 | |
| SCHEMBL1985538 | 0.78 | LCK (0.66) | ENPP1LCKEGFRKDRGAK | |
| SCHEMBL1260737 | 0.78 | ENPP1 (0.54) | ENPP1PDE10ALCKEGFRKDR | |
| SCHEMBL23726845 | 0.77 | ENPP1 (0.53) | ENPP1PDE10ALCKEGFRKDR | |
| SCHEMBL2476964 | 0.77 | RET (0.55) | ENPP1PDE10ALCKEGFRKDR | |
| SCHEMBL3166753 | 0.77 | PDE5A (0.57) | ENPP1LCKEGFRKDRGAK | |
| SCHEMBL364049 | 0.77 | ENPP1 (0.81) | ENPP1LCKEGFRKDRGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4327882-A2 | ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023077083-A1 | ENPP1 INHIBITORS AS INHIBITORS OF METASTASIS | ANGARUS THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2021226136-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | ANGARUS THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2019051269-A1 | ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-03-14 | — | — | WO | disclosed |
| EP-2074115-B1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2018-03-07 | — | — | EP | disclosed |